Evidence map›Paper›PMID 28322306›Full record

ArticleScientific reports2017

Ultrasound mediated delivery of oxygen and LLL12 loaded stimuli responsive microdroplets for the treatment of hypoxic cancer cells.

Jinshun Xu, Shuai Yuan, Jilai Tian, Kyle A Martin, Jinhua Song, Chenglong Li, Zhigang Wang, Jiayuh Lin, Ting Si, Ronald X Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Recent advances in micro-sized oxygen carriers inspired by red blood cells.Science and technology of advanced materials · 2023
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Jinshun XuDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Shuai YuanDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Jilai TianCenter for Childhood Cancer, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Kyle A MartinDepartment of Mechanical Engineering, The Ohio State University, Columbus, OH, 43210 USA.
Jinhua SongDivision of Medicinal Chemistry and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, 43210 USA.
Chenglong LiDivision of Medicinal Chemistry and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, 43210 USA.
Zhigang WangChongqing Key Laboratory of Ultrasound Molecular Imaging, Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Jiayuh LinCenter for Childhood Cancer, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Ting SiDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Ronald X XuDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
The Ohio State University · USNationwide Children's Hospital · USChongqing Medical University · CNSecond Affiliated Hospital of Chongqing Medical University · CNUniversity of Florida · USUniversity of Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LLL12 exhibits high specificity for inhibiting STAT3 phosphorylation and dimerization, and inducing apoptosis to constitutively activated STAT3 cancer cells without cytotoxicity to normal cells with dormant STAT3. However, clinical deployment of LLL12 in cancer treatment is hindered by its low bioavailability and hypoxia-induced resistance. To overcome these limitations, we encapsulate both oxygen and LLL12 in stimuli responsive microdroplets (SRMs) by a gas-driven coaxial flow focusing (CFF) process for ultrasound mediated treatment of hypoxic cancer cells. Our benchtop experiments demonstrate that the CFF process is able to produce SRMs with uniform size distribution, large oxygen loading capacity, high LLL12 encapsulation efficiency, well protection of bioactivity, and steadily long shelf time. The in vitro therapeutic studies in pancreatic cancer cells (PANC-1 and CAPAN-1) demonstrate the immediate release of oxygen and LLL12 in exposure to therapeutic ultrasound pulses as well as the improved anticancer effects under hypoxic conditions. The findings suggest that the proposed oxygen and LLL12 loaded SRMs provide a promising drug delivery strategy for more effective treatment of hypoxic cancer cells.

Indexed as

Ultrasonic WavesAnthraquinonesAntineoplastic AgentsCell Line, TumorCell SurvivalDose-Response Relationship, DrugDrug CompoundingDrug LiberationHumansHypoxiaKineticsOxygenSulfonamidesTumor HypoxiaAnthraquinonesAntineoplastic AgentsLLL12 compoundOxygenSulfonamides

Identifiers

PMID28322306
PMCPMC5359616
OpenAlexW2599005921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.